Anti-Rheumatic Drugs - Sweden

Sweden

The Anti-Rheumatic Drugs market in Sweden is anticipated to witness a substantial growth in revenue, with projections indicating a staggering amount of US$120.90m in 2024.
This growth is expected to continue steadily, with an annual growth rate (CAGR 2024-2029) of 0.72%.
By the year 2029, the market volume is estimated to reach an impressive US$125.30m.
In a global context, it is noteworthy that United States is anticipated to be the leading revenue generator, with an estimated revenue of US$34,700.00m in 2024.
The demand for anti-rheumatic drugs in Sweden is on the rise due to the increasing aging population and high prevalence of rheumatoid arthritis.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Sweden has been experiencing significant growth in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis in Sweden have been showing an increasing preference for biologic drugs over traditional disease-modifying antirheumatic drugs (DMARDs). Biologic drugs have been found to be more effective in treating rheumatoid arthritis and can also be used in combination with DMARDs. Patients are also seeking more personalized treatment options that are tailored to their specific needs.

Trends in the market: The Swedish government has been promoting the use of biologic drugs in the treatment of rheumatoid arthritis. This has led to an increase in the availability of these drugs in the market. Additionally, there has been a rise in the number of clinical trials being conducted in Sweden for new biologic drugs. This has resulted in a higher number of drugs being approved for use in the country.

Local special circumstances: Sweden has a high prevalence of rheumatoid arthritis, with approximately 1% of the population suffering from the disease. The country also has a well-established healthcare system that provides universal coverage to its citizens. This has led to an increase in the availability of anti-rheumatic drugs in the market.

Underlying macroeconomic factors: The Swedish economy has been growing steadily over the past few years. This has resulted in an increase in healthcare spending by the government. Additionally, the aging population in the country has led to a rise in the number of patients suffering from rheumatoid arthritis. This has resulted in an increase in demand for anti-rheumatic drugs in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.